EUROPCR PRESENTATIONS

RDN LEADERS REVIEW KEY FINDINGS

Profs. Felix Mahfoud, Roland Schmieder, and Flavio Ribichini discuss key findings on RDN, including a 26% relative risk reduction in cardiovascular events.*1

VISIT WONDR MEDICAL
An image featuring Profs. Felix Mahfoud, Roland Schmieder, and Flavio Ribichini.
Play Video This will play a video - Video Thumbnail

Prof. Felix Mahfoud discusses real- world outcomes of RDN from the GLOBAL SYMPLICITY REGISTRY.

Play Video This will play a video - Video Thumbnail

Prof. Andrew Sharp explores the science of RDN from a proceduralist's perspective.

Play Video This will play a video - Video Thumbnail

Dr. David Kandzari provides an overview of the latest RDN data, including data on the role of patient preference.

ESH-ISH JOINT MEETING PRESENTATIONS

Play Video This will play a video - Dr. Markus Schlaich

Prof. Flavio Ribichini shares his real- world experience using RDN to treat hypertension in a high-risk population with chronic kidney disease.

Play Video This will play a video - Prof. Roland Schmieder

Prof. Roland Schmieder presents key findings on cardiovascular risk reduction after RDN from an analysis of the GLOBAL SYMPLICITY REGISTRY.

Play Video This will play a video - Dr. Isabella Sudano

Prof. Isabella Sudano discusses which patients are best suited for RDN, including how to incorporate patient preference.

TCT 2020 INTERVIEWS & SYMPOSIA PRESENTATIONS

Play Video This will play a video - Dr. Markus Schlaich

Prof. Markus Schlaich discusses GLOBAL SYMPLICITY REGISTRY data on RDN in patients with resistant hypertension.

INSIGHTS  FROM TCT CONNECT 2020

Watch interviews with experts on the latest data in RDN from TCT Connect 2020.

Play Video This will play a video - Dr. Andrew Sharp

Prof. Andrew Sharp reviews data on the durability of RDN from animal histology and insights into human renal anatomy.

A Pivotal Moment for RDN - (12:04)

Dr. David Kandzari discusses primary results from the SPYRAL HTN-OFF MED Pivotal Trial.
More information (see more) Less information (see less)

Data and Science Revisited - (12:47)

Dr. Flavio Ribichini recaps the history and scientific basis behind renal denervation.
More information (see more) Less information (see less)

Real-World Experience of RDN - (11:08)

Prof. Markus Schlaich discusses safety, efficacy and patient selection insights from the largest study of renal denervation.
More information (see more) Less information (see less)

Clinical Case Discussion - (28:15)

Dr. Roland Schmieder and Dr. TD Wang discuss an actual RDN case as well as the related issues of non-adherence and patient preference.
More information (see more) Less information (see less)

Used with permission from TCT Connect 2020.

PCR E-COURSE 2020 PRESENTATIONS

PIVOTAL MOMENT FOR RDN

Dr. Konstantinos Tsioufis and Dr. Michael Böhm present the clinical results from the SPYRAL HTN-OFF MED Pivotal trial.

Advances in the Renal Denervation Procedure - (20:13)

Renal Denervation: Putting Guidelines into Practice - (15:17)

Blood Pressure Outcomes: Renal Denervation in Various Patient Subgroups - (06:45)

Addressing the Population Question: Interesting Case Profiles in Renal Denervation - (15:52)

Used with permission from PCROnline 2020.

ACC 2020 WORLD CONGRESS

SEE OUR LATE-BREAKING PRESENTATION

If you missed our online late- breaking presentation on SPYRAL HTN-OFF MED Pivotal data, you can watch it now.

EXAMINING THE EVIDENCE

See clinical studies that evaluate the safety and efficacy of the Symplicity™ Spyral RDN system.

REVIEW CLINICAL STUDIES

SEE HOW RDN WORKS

Learn more about the renal denervation procedure.

GET PROCEDURE DETAILS

UNDERSTAND RDN TREATMENT CRITERIA

Read guidelines for ideal RDN candidates from around the world.

EXPLORE PATIENT SELECTION

Connect with a Medtronic representative

Request more information

request more information

Contact us

request more information

Contact us
*

For patients in the GLOBAL SYMPLICITY REGISTRY, compared to a modeled control group.

1

Schmieder R, Böhm M, Schlaich M, et al. Modeled Clinical Event Reductions at Three Years in High-Risk Hypertension Patients Treated with Renal Denervation. Presented at Deutsche Gesellschaft fur Kardiologie 2021.

Disclaimer: This page may include information about products that may not be available in your region or country. Please consult the approved indications for use. Content on specific Medtronic products is not intended for users in markets that do not have authorization for use.

CONTACT

Register for updates about Medtronic Renal Denervation.

Sign Up